NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 8 July 2025

**Location:** Hybrid via Manchester offices and Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Richard Nicholas (Vice Chair) Present for all items
3. Dr Amit Parekh Present for items 1 to 4.2.2
4. Professor Andrew Renehan Present for items 5 to 6.2.2
5. Dr Arpit Srivastava Present for all items
6. Dr David Foreman Present for all items
7. Elizabeth Thurgar Present for all items
8. Iain McGowan Present for all items
9. John Hampson Present for all items
10. Dr Jonathan Sive Present for all items
11. Dr Kate Ren Present for all items
12. Dr Mark Corbett Present for all items
13. Michael Chambers Present for all items
14. Dr Pedro Saramago Goncalves Present for all items
15. Dr Satish Venkateshan Present for items 5 to 6.2.2
16. Stella O’Brien Present for all items
17. Ugochi Nwulu Present for all items

NICE staff (key players) present

Ross Dent, Associate Director Items 1 to 4.2.2, 6 to 6.2.2

Louise Jafferally, Project Manager Items 1 to 4.2.2

Alexandra Filby, Heath Technology Assessment Adviser Items 1 to 4.2.2

Victoria Gillis-Elliott, Heath Technology Assessment Analyst Items 1 to 4.2.2

Ian Watson, Associate Director Items 5 to 5.2.2

Leena Issa, Project Manager Items 5 to 5.2.2

Caron Jones, Heath Technology Assessment Adviser Items 5 to 5.2.2

Emma McCarthy, Heath Technology Assessment Analyst Items 5 to 5.2.2

Kate Moore, Project Manager Items 6 to 6.2.2

Harsimran Sarpal, Heath Technology Assessment Adviser Items 6 to 6.2.2

Eleanor Donegan, Heath Technology Assessment Adviser Items 6 to 6.2.2

External assessment group representatives present

Geoff Frampton, Southampton Health Technology Assessment Centre (SHTAC) Items 1 to 4.1.3

Fay Chinnery, Southampton Health Technology Assessment Centre (SHTAC) Items 1 to 4.1.3

Brian Rice, Decision Support Unit (DSU) Items 5 to 5.1.3

Jill Colquitt, Birmingham Centre for Evidence and Implementation Science (BCEIS) Items 5 to 5.1.3

Peter Auguste, Birmingham Centre for Evidence and Implementation Science (BCEIS) Items 5 to 5.1.3

Archie Walters, BMJ Technology Assessment Group Items 6 to 6.1.3

Melina Vasileiou, BMJ Technology Assessment Group Items 6 to 6.1.3

Clinical, Patient & NHS England experts present

Cathy Burton, Consultant Haematologist, clinical expert nominated by Roche Items 1 to 4.1.3

Sridhar Chaganti, Consultant Haematologist, clinical expert nominated by Roche Items 1 to 4.1.3

James Richardson, National Specialty Advisor (Cancer Drugs), commissioning expert Items 1 to 4.1.3

Manoel Filho, Community expert, nominated by UK-CAB Items 5 to 5.1.3

Greg Owen, Community expert, nominated by Terrence Higgins Trust Items 5 to 5.1.3

Rachael Jones, Consultant at Chelsea and Westminster Hospital NHS Foundation Trust, clinical expert nominated by NHS England Items 5 to 5.1.3

Michael Brady, Consultant in HIV and Sexual Health at King’s College Hospital, clinical expert nominated by ViiV Items 5 to 5.1.3

Anna Kafkalia, National Programme of Care Manager – Blood and Infection at NHSE, commissioning expert nominated by NHS England Items 5 to 5.1.3

Hamish Mohammed, Consultant HIV/STI Surveillance and Prevention Scientist Blood Safety, Hepatitis, Sexually Transmitted Infections (STIs) and HIV Division, UKHSA clinical expert nominated by UKHSA Items 5 to 5.1.3

Tamara Djuretic, Head of HIV Section and Consultant Epidemiologist, Blood Safety, Hepatitis, Sexually Transmitted Infections (STIs) and HIV Division, UKHSA, clinical expert nominated by UKHSA Items 5 to 5.1.3

Professor Patrick Yu Wai Man, Professor of Ophthalmology, clinical expert nominated by Royal College of Ophthalmologists Items 6 to 6.1.3

Professor Marcela Votruba, Professor and Hon. Consultant in Ophthalmology, clinical expert nominated by The Royal College of Ophthalmologists Items 6 to 6.1.3

Lily Mumford, Patient expert Items 6 to 6.1.3

Mary Clifford, Patient expert nominated by the LHON Society Items 6 to 6.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair, Prof. Stephen O’Brien, welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Alex Cale, Clare Offer, Dawn Cooper, Louise Hunt, Dr Prithwiraj Das, and Richard Boldero.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The Chair asked the committee to submit their comments on the minutes of the committee meeting held on 11th June 2025.

### Appraisal of Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma [ID6202]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Roche Products.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11164).
     3. The chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Elizabeth Thurgar, Dr Amit Parekh, and Stella O’Brien.
  2. Part 2 – Closed session (company representatives, professional experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the [topic webpage](https://www.nice.org.uk/guidance/indevelopment/gid-ta11164) in due course.

### Appraisal of Cabotegravir for preventing HIV-1 in adults and young people [ID6255]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from ViiV Healthcare.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11304).
     3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by the chair.
  2. Part 2 – Closed session (company representatives, professional experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the [topic webpage](https://www.nice.org.uk/guidance/indevelopment/gid-ta11304) in due course.

### Appraisal of Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over [ID547]

* 1. Part 1 – Open session
     1. The vice-chair, Dr Richard Nicholas, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Chiesi.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11288).
     3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by the vice-chair.
  2. Part 2 – Closed session (company representatives, professional experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the [topic webpage](https://www.nice.org.uk/guidance/indevelopment/gid-ta11288) in due course.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 12 August 2025 and will start promptly at 9am.